Tag: Biosimilars

The 2025 event to explore how Indian pharmaceutical companies can capture new growth in generics and biosimilars while navigating competition and regulatory complexities

Dr Cyrus Karkaria, President-Biotechnology, Lupin Limited shares his views on the current market trends and growth prospects of Indian biosimilars industry, company’s key offerings, ongoing initiatives, and future plans

The Cover Story analyses the potential impact of significant uncertainty due to the proposed reciprocal tariffs with insights from Vishal Dhikale, Associate Vice President, Avalon Consulting. Read interview of Puneeth Kumar KT, Business Director for Planetary Health Biosolutions, Novonesis South Asia and Expert Insights by Mahesh Ramanujam, President & CEO, Global Network for Zero; and Dr Vidhi Bhanushali, CEO and Co-founder, scanO.

The Cover Story analyzes the blockbuster opportunity for India's biopharma industry. Read interviews of Dr Cyrus Karkaria, President-Biotechnology, Lupin Limited; Sachin Joshi, MD & Founder, PharmNXT Biotech; Mandeep Singh Kumar, MD and Vice President, Medtronic India; and Harshvardhan Bhagchandka, President, IPL Biologicals

Accord BioPharma (A division of Intas Pharmaceuticals) anticipates a commercial launch of IMULDOSA in the first half of 2025

GaBI Journal publishes peer-reviewed study highlighting six policy recommendations for expanding access to affordable healthcare

Fourteen categories celebrate groundbreaking achievements and introduce new honors for emerging leaders

The company’s success in vaccine trials is driven by its extensive site network, comprising over 130 locations across India

Under the terms of this settlement agreement, Biocon Biologics has resolved patent disputes with Janssen to secure market entry dates in Europe, the UK, Canada, and Japan

Tirzepatide’s debut as the first dual GIP and GLP-1 receptor agonist for obesity in China strengthens Eli Lilly’s presence